 |
|
|
|
|
|
||
      |
|
||
 |
 |
|
|
      |
|||
 | |
| School of Medicine Home > Research > Faculty Research > Sikic Lab |
| |
| |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
Clinical interests: general oncology, cancer pharmacology, clinical trials of modulation of drug resistance, and integration of novel targeted drugs into cancer therapies. Research
interests: mechanisms of resistance to anticancer drugs, particularly
multidrug resistance (MDR1/P-glycoprotein), resistance to taxanes, and pharmacogenetics
and pharmacogenomics. Our goals are to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I, II and III clinical trials, and translational studies of molecular determinants of therapeutic response and toxicity. Laboratory projects include studies of the multidrug transporter, P-glycoprotein, regulation of the MDR1 (ABCB1) gene, taxane resistance mechanisms including tubulin gene expression, and pharmacogenetic and genomic studies related to clinical trials in colorectal cancers, pediatric leukemias, and brain tumors. Clinical investigations include
the prognostic significance of resistance gene expression in cancers,
pharmacokinetic consequences of MDR modulation, Phase I and II
trials of new tyrosine kinase inhibitors both as single agents
and integrated with standard chemotherapies, and a Phase I trial
of an agonistic human monoclonal antibody against TRAIL-R2.
|
|||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
